2019
Palbociclib and Fulvestrant Act in Synergy to Modulate Central Carbon Metabolism in Breast Cancer Cells
Warth B, Palermo A, Rattray NJW, Lee NV, Zhu Z, Hoang LT, Cai Y, Mazurek A, Dann S, VanArsdale T, Fantin VR, Shields D, Siuzdak G, Johnson CH. Palbociclib and Fulvestrant Act in Synergy to Modulate Central Carbon Metabolism in Breast Cancer Cells. Metabolites 2019, 9: 7. PMID: 30609717, PMCID: PMC6359333, DOI: 10.3390/metabo9010007.Peer-Reviewed Original ResearchProgression-free survivalBreast cancer cell metabolismEstrogen receptor antagonistCyclin-dependent kinase 4Breast cancer cellsCancer cell metabolismCombination chemotherapyMCF-7 cellsReceptor antagonistCombination chemotherapeuticsSurvival advantageSelective metabolic pathwaysMetabolic disruptionCancer cellsMetabolic pathwaysKinase 4Cancer metabolismSelective inhibitorPalbociclibSame metabolic pathwayDrugsMetabolismTranscriptomic changesCell modelCell metabolism
2011
Xenobiotic Metabolomics: Major Impact on the Metabolome
Johnson CH, Patterson AD, Idle JR, Gonzalez FJ. Xenobiotic Metabolomics: Major Impact on the Metabolome. The Annual Review Of Pharmacology And Toxicology 2011, 52: 37-56. PMID: 21819238, PMCID: PMC6300990, DOI: 10.1146/annurev-pharmtox-010611-134748.Peer-Reviewed Original Research